bay2402234  (MedChemExpress)

Journal: Discover Oncology

Article Title: TP53-dependent antitumor effects of DHODH Inhibition in nasopharyngeal carcinoma

doi: 10.1007/s12672-025-03857-6

Figure Lengend Snippet: BAY2402234 inhibits nasopharyngeal carcinoma cell viability, induces apoptosis, and suppresses migration and invasion. A – C Dose-dependent inhibition of cell viability by BAY2402234 in C666-1 A , NPC/HK1 B , and NP69 C nasopharyngeal cell lines after 24 h, 48 h, and 72 h of treatment. Cell viability was assessed as a percentage of that of the 0 nM control. D – E Flow cytometry analysis of apoptosis using Annexin V-YSFluor 647/PI double staining in C666-1 D and NPC/HK1 E cells after treatment with BAY2402234 (8 nM) for 48 h. Representative flow cytometry plots (left) and quantification of Annexin V-positive cells (right) are shown. **** P < 0.0001. F – G Transwell migration assay showing decreased migratory ability of C666-1 F and NPC/HK1 G cells treated with BAY2402234 (8 nM) for 24 h. Representative images (left) and quantification of migrated cells (right) are shown. ** P < 0.01; *** P < 0.001. H – I Transwell invasion assay showing the reduced invasive capacity of C666-1 H and NPC/HK1 I cells treated with BAY2402234 (8 nM) for 24 h. Representative images (left) and quantification of invaded cells (right) are shown. ** P < 0.01; *** P < 0.001

Article Snippet: The DHODH inhibitor BAY2402234 (MCE, Cat: HY-112645) was dissolved in DMSO to prepare an 80 μM stock solution, which was stored at -80 °C in the dark.

Techniques: Migration, Inhibition, Control, Flow Cytometry, Double Staining, Transwell Migration Assay, Transwell Invasion Assay

Journal: Discover Oncology

Article Title: TP53-dependent antitumor effects of DHODH Inhibition in nasopharyngeal carcinoma

doi: 10.1007/s12672-025-03857-6

Figure Lengend Snippet: BAY2402234 treatment induces changes in gene expression and activates the TP53 signaling pathway in nasopharyngeal carcinoma cells. A Principal component analysis (PCA) of RNA-seq data from control and BAY2402234-treated nasopharyngeal carcinoma cells, which revealed distinct clustering of the treatment groups. B Volcano plot depicting genes that were differentially expressed after BAY2402234 treatment. The red dots represent upregulated genes, the blue dots represent downregulated genes, and the gray dots represent genes with no significant changes in expression. C – D KEGG ( C ) and GO D enrichment analyses of differentially expressed genes after BAY2402234 treatment. The bubble size represents the gene count, and the color intensity indicates the adjusted p value. E – F Gene Set Enrichment Analysis (GSEA) ridge plots showing enriched KEGG pathways E and GO terms F in BAY2402234-treated cells compared with control cells. The color indicates the adjusted p value, and the x-axis represents the log2 fold change. G – H TP53 gene expression in BAY2402234-treated and control cells was measured via qRT-PCR. The data are presented as RPM values G and relative expression H . * P < 0.05. I – J Western blot analysis I and quantification J of P53 protein expression in control and BAY2402234-treated cells. β-actin was used as a loading control. * P < 0.05. (K) Pathway map of the P53 signaling pathway with differentially expressed genes highlighted according to their log2-fold change (log2FC). Red: genes upregulated after BAY2402234 treatment. White: genes with no significant changes in expression. Green: genes not expressed

Article Snippet: The DHODH inhibitor BAY2402234 (MCE, Cat: HY-112645) was dissolved in DMSO to prepare an 80 μM stock solution, which was stored at -80 °C in the dark.

Techniques: Gene Expression, RNA Sequencing, Control, Expressing, Quantitative RT-PCR, Western Blot